C

Coeptis Therapeutics Inc
NASDAQ:COEP

Watchlist Manager
Coeptis Therapeutics Inc
NASDAQ:COEP
Watchlist
Price: 12.6 USD 1.9%
Market Cap: 67.3m USD

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Coeptis Therapeutics Inc
NASDAQ:COEP
66m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
522.8B USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
273.7B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
207.6B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219.4B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
275.5B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
No Stocks Found

Market Distribution

Not Available
No Country distribution data available for this multiple

Coeptis Therapeutics Inc
Glance View

Market Cap
67.3m USD
Industry
N/A

Coeptis Therapeutics, Inc. is a pharmaceutical company focused on the development of therapeutics and technologies to disrupt conventional treatment paradigms. The company is headquartered in Wexford, Pennsylvania and currently employs 4 full-time employees. The company went IPO on 2002-07-29. The Company, through its subsidiary, Coeptis Pharmaceuticals, Inc., is engaged in developing cell therapy platforms for cancer. Its product portfolio comprises CD38-GEAR-NK and CD38-Diagnostic. The firm's CD38-GEAR-NK is an autologous, natural killer (NK) cell-based therapeutic that is derived from a patient’s own cells and gene-edited to enable combination therapy with anti-CD38 monoclonal antibodies (mAbs). Its CD38-Diagnostic is an in vitro screening tool that is intended to provide the ability to pre-determine, which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as monotherapy or in combination with CD38-GEAR-NK.

COEP Intrinsic Value
Not Available
C
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top